We are live on ! Find out more
5.07 USD
-0.25
4.7%
At close Updated Aug 27, 4:00 PM EDT
1 day
-4.7%
5 days
-0.39%
1 month
-2.5%
3 months
-19.52%
6 months
-49.7%
Year to date
-30.83%
1 year
-64.94%
5 years
-99.85%
10 years
-99.92%
 

About: PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

Employees: 41

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
Seeking Alpha
13 days ago
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
Neutral
PRNewsWire
14 days ago
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Neutral
PRNewsWire
15 days ago
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Thursday, August 13, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Neutral
PRNewsWire
22 days ago
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt.
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Neutral
PRNewsWire
23 days ago
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 11 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 10, 2026 Location: Virtual Canaccord Genuity 46 th Annual Growth Conference Fireside Chat: August 11, 2026, at 11:30 AM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Neutral
PRNewsWire
27 days ago
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Neutral
PRNewsWire
28 days ago
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Neutral
Seeking Alpha
2 months ago
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
Neutral
Seeking Alpha
3 months ago
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $2.1 per share a year ago.
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
Price charts implemented using Lightweight Charts™